- Home
- ILPT vs AVIR Comparison
ILPT vs AVIR Comparison
Compare ILPT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILPT | AVIR |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.0M | 434.5M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ILPT | AVIR |
|---|---|---|
| Price | $8.66 | $4.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.05 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 491.3K | 259.4K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 31.51 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $2.78 |
| 52 Week High | $9.17 | $6.45 |
Technical Indicators
Market Signals| Indicator | ILPT | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 49.33 |
| Support Level | $8.47 | $4.10 |
| Resistance Level | $9.16 | $4.59 |
| Average True Range (ATR) | 0.35 | 0.18 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 53.85 | 81.18 |
Price Performance
Historical ComparisonAbout ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.